279 related articles for article (PubMed ID: 15598977)
1. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team.
Noy A; Scadden DT; Lee J; Dezube BJ; Aboulafia D; Tulpule A; Walmsley S; Gill P
J Clin Oncol; 2005 Feb; 23(5):990-8. PubMed ID: 15598977
[TBL] [Abstract][Full Text] [Related]
2. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma.
Tulpule A; Scadden DT; Espina BM; Cabriales S; Howard W; Shea K; Gill PS
J Clin Oncol; 2000 Feb; 18(4):716-23. PubMed ID: 10673512
[TBL] [Abstract][Full Text] [Related]
3. Long-term clinical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy.
Cattelan AM; Calabrò ML; De Rossi A; Aversa SM; Barbierato M; Trevenzoli M; Gasperini P; Zanchetta M; Cadrobbi P; Monfardini S; Chieco-Bianchi L
Int J Oncol; 2005 Sep; 27(3):779-85. PubMed ID: 16077928
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study.
Dezube BJ; Krown SE; Lee JY; Bauer KS; Aboulafia DM
J Clin Oncol; 2006 Mar; 24(9):1389-94. PubMed ID: 16549833
[TBL] [Abstract][Full Text] [Related]
5. The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma.
Bower M; Weir J; Francis N; Newsom-Davis T; Powles S; Crook T; Boffito M; Gazzard B; Nelson M
AIDS; 2009 Aug; 23(13):1701-6. PubMed ID: 19550283
[TBL] [Abstract][Full Text] [Related]
6. Open-label phase I study of combination therapy with zidovudine and interferon-beta in patients with AIDS-related Kaposi's sarcoma: AIDS Clinical Trials Group Protocol 057.
Miles S; Levine A; Feldstein M; Carden J; Cabriallas S; Marcus S; Mitsuyasu R; Gill P
Cytokines Cell Mol Ther; 1998 Mar; 4(1):17-23. PubMed ID: 9557213
[TBL] [Abstract][Full Text] [Related]
7. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.
Bihl F; Mosam A; Henry LN; Chisholm JV; Dollard S; Gumbi P; Cassol E; Page T; Mueller N; Kiepiela P; Martin JN; Coovadia HM; Scadden DT; Brander C
AIDS; 2007 Jun; 21(10):1245-52. PubMed ID: 17545700
[TBL] [Abstract][Full Text] [Related]
8. AIDS-related Kaposi's sarcoma patients with visceral manifestations. Response to human chorionic gonadotropin preparations.
Hermans P; Clumeck N; Picard O; van Vooren JP; Duriez P; Zucman D; Bryant JL; Gill P; Lunardi-Iskandar Y; Gallo RC
J Hum Virol; 1998; 1(2):82-9. PubMed ID: 10195236
[TBL] [Abstract][Full Text] [Related]
9. AIDS-related Kaposi's Sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals.
Nasti G; Talamini R; Antinori A; Martellotta F; Jacchetti G; Chiodo F; Ballardini G; Stoppini L; Di Perri G; Mena M; Tavio M; Vaccher E; D'Arminio Monforte A; Tirelli U;
J Clin Oncol; 2003 Aug; 21(15):2876-82. PubMed ID: 12885804
[TBL] [Abstract][Full Text] [Related]
10. The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma.
Gill PS; Lunardi-Ishkandar Y; Louie S; Tulpule A; Zheng T; Espina BM; Besnier JM; Hermans P; Levine AM; Bryant JL; Gallo RC
N Engl J Med; 1996 Oct; 335(17):1261-9. PubMed ID: 8857005
[TBL] [Abstract][Full Text] [Related]
11. [AIDS-associated Kaposi's sarcoma: 22 cases].
Dhrif AS; Kilani B; Ammari L; Kanoun F; Tiouri H; Ben Chaaben T
Tunis Med; 2007 Jun; 85(6):494-9. PubMed ID: 17644904
[TBL] [Abstract][Full Text] [Related]
12. [Kaposi sarcoma in HIV patients: Response to antiretroviral treatment and chemotherapy].
Lasso M; Pérez J; Noriega L; Malebrán A; Espinoza S
Rev Med Chil; 2003 May; 131(5):483-90. PubMed ID: 12879808
[TBL] [Abstract][Full Text] [Related]
13. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy.
Pellet C; Chevret S; Blum L; Gauvillé C; Hurault M; Blanchard G; Agbalika F; Lascoux C; Ponscarme D; Morel P; Calvo F; Lebbé C
J Invest Dermatol; 2001 Oct; 117(4):858-63. PubMed ID: 11676823
[TBL] [Abstract][Full Text] [Related]
14. Regression of AIDS-related Kaposi's sarcoma following combined antiretroviral treatment.
Monticelli A; Lewi D; Salomon H; Pampuro S; Libonatti O; Jauregui Rueda H; Hodara V
Rev Argent Microbiol; 2000; 32(4):206-8. PubMed ID: 11149154
[TBL] [Abstract][Full Text] [Related]
15. Profile of patients with Kaposi's sarcoma in the era of highly active antiretroviral therapy.
Gallafent JH; Buskin SE; De Turk PB; Aboulafia DM
J Clin Oncol; 2005 Feb; 23(6):1253-60. PubMed ID: 15718323
[TBL] [Abstract][Full Text] [Related]
16. All-trans retinoic acid for the treatment of AIDS-related Kaposi's sarcoma: results of a pilot phase II study.
Gill PS; Espina BM; Moudgil T; Kidane S; Esplin JA; Tulpule A; Levine AM
Leukemia; 1994; 8 Suppl 3():S26-32. PubMed ID: 7808021
[TBL] [Abstract][Full Text] [Related]
17. Cellular immune responses and disease control in acute AIDS-associated Kaposi's sarcoma.
Bihl F; Berger C; Chisholm JV; Henry LM; Bertisch B; Trojan A; Nadal D; Speck RF; Flepp M; Brander C; Mueller NJ;
AIDS; 2009 Sep; 23(14):1918-22. PubMed ID: 19609199
[TBL] [Abstract][Full Text] [Related]
18. Antiviral activity of low-dose alovudine in antiretroviral-experienced patients: results from a 4-week randomized, double-blind, placebo-controlled dose-ranging trial.
Ghosn J; Quinson AM; Sabo N; Cotte L; Piketty C; Dorléacq N; Bravo ML; Mayers D; Harmenberg J; Mårdh G; Valdez H; Katlama C
HIV Med; 2007 Apr; 8(3):142-7. PubMed ID: 17461857
[TBL] [Abstract][Full Text] [Related]
19. Imatinib-induced regression of AIDS-related Kaposi's sarcoma.
Koon HB; Bubley GJ; Pantanowitz L; Masiello D; Smith B; Crosby K; Proper J; Weeden W; Miller TE; Chatis P; Egorin MJ; Tahan SR; Dezube BJ
J Clin Oncol; 2005 Feb; 23(5):982-9. PubMed ID: 15572730
[TBL] [Abstract][Full Text] [Related]
20. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era.
El Amari EB; Toutous-Trellu L; Gayet-Ageron A; Baumann M; Cathomas G; Steffen I; Erb P; Mueller NJ; Furrer H; Cavassini M; Vernazza P; Hirsch HH; Bernasconi E; Hirschel B;
AIDS; 2008 May; 22(9):1019-28. PubMed ID: 18520345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
